Timothy K. MacLachlan

Novartis (Switzerland) — Switzerland

Medicine · Health Sciences

24h-index2.1kcitations73works9.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(25), CRISPR and Genetic Engineering(13), CAR-T cell therapy research(10), DNA Repair Mechanisms(8), Virus-based gene therapy research(8)

Publications73 total

Comparative assessment of the transduction efficiency and safety associated with the delivery of AAV9-GFP vector via lumbar puncture to cynomolgus macaques with and without anti-AAV9 pre-existing antibodies
Molecular Therapy — Methods & Clinical Development·2024· 1 citedOpen Access
The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases
Nature Reviews Drug Discovery·2024· 18 cited
CRISPR-Cas9 Editing of the <i>HBG1</i> and <i>HBG2</i> Promoters to Treat Sickle Cell Disease
New England Journal of Medicine·2023· 138 citedOpen Access
CRISPR/Cas9 Genome-Edited Autologous Hematopoietic Stem Cell Transplantation Therapies for Sickle Cell Disease
Blood·2022
Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies
Human Gene Therapy·2022· 13 citedOpen Access
Current global regulatory landscape for biodistribution &amp; shedding assessment of rAAV gene therapies &amp; recommendations of the IMI ARDAT consortium on future directions
Cell and Gene Therapy Insights·2022· 3 citedOpen Access
Nonclinical Safety Evaluation of Therapies for Rare Diseases
2021
Nonclinical Development of Anticancer Biotherapeutics
2021
Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules – A survey of industry 2008–2019
Regulatory Toxicology and Pharmacology·2021· 12 cited
Preclinical Evaluation and Translational Development of Cell and Gene Therapies
2020
Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies
Regulatory Toxicology and Pharmacology·2020· 4 cited
Nonclinical Studies that Support Viral Vector-Delivered Gene Therapies: An EFPIA Gene Therapy Working Group Perspective
Molecular Therapy — Methods & Clinical Development·2020· 17 citedOpen Access
Safety of cell therapy products: in-vitro methods to assess the tumorigenicity of human cell-based therapeutic products
Cytotherapy·2020· 3 cited
Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider
Cytotherapy·2019· 150 citedOpen Access
Nonclinical Safety Evaluation of Advanced Therapies
Toxicologic Pathology·2018
Current Strategies in the non-clinical safety assessment of biologics: New Targets, New Molecules, New Challenges (A report of the 2016 Annual US BioSafe General Membership meeting)
The Novartis Repository (Novartis)·2018
Nonclinical safety evaluation of T-cell based immunotherapies
2018
Nonclinical Safety Evaluation of scAAV8- RLBP1 for Treatment of RLBP1 Retinitis Pigmentosa
Molecular Therapy — Methods & Clinical Development·2017· 38 citedOpen Access
Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use
mAbs·2017· 30 citedOpen Access
Corrigendum to “Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics” [Regul. Toxicol. Pharmacol. (2017) 221–230]
Regulatory Toxicology and Pharmacology·2017
page 1 of 4Next →

Frequent Co-authors

Wafik S. El‐Deiry(15), Antonio Giordano(7), Antonio De Luca(5), Mark Milton(5), Laura Andrews(5), Nianli Sang(4), Diann Blanset(4), Joy Cavagnaro(4), Luigi Bagella(3), Kumaravel Somasundaram(2), Magda Sgagias(2), Kenneth H. Cowan(2), Michael Lukason(2), Margaret E. Collins(2), Elizabeth DuFresne(2), Gábor Veres(2), Abraham Scaria(2), Samuel C. Wadsworth(2), Rishu Takimoto(2), Yoji Sato(2)